Syndax shares fall 17% after calling it quits on Niktimvo fibrosis program
Published . Updated .
Syndax shares fall 17% after calling it quits on Niktimvo fibrosis program Fierce Pharma
Directly affected
- No company is named in this report.
Indirectly affected
- NAMS NEW AMSTERDAM PHARMA CO ORDINARY SHARES
GA selected NAMS as a RELATED security because its canonical security name directly matches this event's themes: pharma, shares. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- DVA DaVita HealthCare Partners, Inc.
GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
Syndax shares fall 17% after calling it quits on Niktimvo fibrosis program Fierce Pharma
Source: Fierce Pharma
Price since this story was published: NewAmsterdam Pharma Co N.V (NAMS)
Since the first closing price after “Syndax shares fall 17% after calling it quits on Niktimvo fibrosis program,” NewAmsterdam Pharma Co N.V (NAMS) is +2.37%. The S&P 500 fund (SPY) is -0.40% over the same days, a +2.77% difference versus the market.
| Company | When | Move | Status |
|---|---|---|---|
| Acadia Healthcare (ACHC) | that day | +0.50% | final price |
| Acadia Healthcare (ACHC) | the next day | +5.29% | final price |
| Acadia Healthcare (ACHC) | two days later | +3.19% | final price |
| Acadia Healthcare (ACHC) | three days later | -0.33% | final price |
| Acadia Healthcare (ACHC) | three days earlier | -5.32% | final price |
| Acadia Healthcare (ACHC) | five days earlier | -3.46% | final price |
| Ascendis Pharma A/S (ASND) | that day | -1.62% | final price |
| Ascendis Pharma A/S (ASND) | the next day | +0.04% | final price |
| Ascendis Pharma A/S (ASND) | two days later | -0.14% | final price |
| Ascendis Pharma A/S (ASND) | three days later | -0.76% | final price |
| Ascendis Pharma A/S (ASND) | three days earlier | -1.88% | final price |
| Ascendis Pharma A/S (ASND) | five days earlier | -0.35% | final price |
| aTYR PHARMA (ATYR) | that day | -7.79% | final price |
| aTYR PHARMA (ATYR) | the next day | -16.23% | final price |
| aTYR PHARMA (ATYR) | two days later | -14.52% | final price |
| aTYR PHARMA (ATYR) | three days later | -18.17% | final price |
| aTYR PHARMA (ATYR) | three days earlier | +18.40% | final price |
| aTYR PHARMA (ATYR) | five days earlier | +30.15% | final price |
| BridgeBio Pharma (BBIO) | that day | -3.73% | final price |
| BridgeBio Pharma (BBIO) | the next day | -1.23% | final price |
| BridgeBio Pharma (BBIO) | two days later | +2.10% | final price |
| BridgeBio Pharma (BBIO) | three days later | +0.97% | final price |
| BridgeBio Pharma (BBIO) | three days earlier | -1.08% | final price |
| BridgeBio Pharma (BBIO) | five days earlier | +1.84% | final price |
| Davita (DVA) | that day | +0.34% | final price |
| Davita (DVA) | the next day | -0.54% | final price |
| Davita (DVA) | two days later | +4.08% | final price |
| Davita (DVA) | three days later | +2.99% | final price |
| Davita (DVA) | three days earlier | -2.48% | final price |
| Davita (DVA) | five days earlier | -0.74% | final price |
Disclosure records for NewAmsterdam Pharma Co N.V (NAMS) within two months of 13 Oct 2026
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around NewAmsterdam Pharma Co N.V (NAMS)
Companies carried with this story
- NAMS NewAmsterdam Pharma Co N.V
In “Syndax shares fall 17% after calling it quits on Niktimvo fibrosis program,” NewAmsterdam Pharma Co N.V (NAMS) is linked, with no stored direction, medium confidence. Reason on file: GA selected NAMS as a RELATED security because its canonical security name directly matches this event's themes: pharma, shares. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ACHC Acadia Healthcare
For “Syndax shares fall 17% after calling it quits on Niktimvo fibrosis program,” Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ASND Ascendis Pharma A/S
In “Syndax shares fall 17% after calling it quits on Niktimvo fibrosis program,” Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence. Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ATYR aTYR PHARMA
aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence in the 13 Oct 2026 story “Syndax shares fall 17% after calling it quits on Niktimvo fibrosis program.” Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BBIO BridgeBio Pharma
BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence in the 13 Oct 2026 story “Syndax shares fall 17% after calling it quits on Niktimvo fibrosis program.” Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DVA Davita
Davita (DVA) is linked, with no stored direction, medium confidence in the 13 Oct 2026 story “Syndax shares fall 17% after calling it quits on Niktimvo fibrosis program.” Reason on file: GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
NewAmsterdam Pharma Co N.V (NAMS)
On 13 Oct 2026, “Syndax shares fall 17% after calling it quits on Niktimvo fibrosis program” is the story that connects NewAmsterdam Pharma Co N.V (NAMS) to this story.
For NewAmsterdam Pharma Co N.V (NAMS), the reason on file says GA selected NAMS as a RELATED security because its canonical security name directly matches this event's themes: pharma, shares. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
A second company, Acadia Healthcare (ACHC), is listed for a different reason: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Dates in the story, and the NewAmsterdam Pharma Co N.V (NAMS) price range
ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. ASND traded between 219.69 and 240.84 across 20 sessions. The latest close on file is 229.99. NAMS traded between 19.58 and 25.10 across 20 sessions. The latest close on file is 20.49.
How strong the case is around NewAmsterdam Pharma Co N.V (NAMS)
46 out of 100
“Syndax shares fall 17% after calling it quits on Niktimvo fibrosis program” scores 46 out of 100. The score uses 1 sources, and 6 linked companies.